Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD-SIB
2025-521161-27-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cannabidiol in intellectual disability (ID), Neurodevelopmental disorder (NDD) and Self-injurious behavior, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary efficacy: reduction in self-injurious behavior frequency at Day 56. Planned start Oct 2025; status: authorised.
02
Drugs
cannabidiol
03
Conditions
intellectual disability (ID)Neurodevelopmental disorder (NDD)Self-injurious behavior
Beyond the preview
Go deeper on 2025-521161-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521161-27-00.